Literature DB >> 3096053

Effects of transferrin genetic phenotypes on total iron-binding capacity.

C T Wong, N Saha.   

Abstract

Serum transferrin level and total iron-binding capacity (TIBC) were studied in a group of 297 healthy adult male subjects having HbAA and G6PDB+ phenotypes by standard chemical and immunoelectrophoretic techniques to examine the influence of different transferrin variants on these parameters. TIBC (67.1 +/- 13.4 mumol/l) and transferrin concentrations (27.0 +/- 3.95 mumol/l) for the whole group were found to be within reported normal values. Serum transferrin concentrations of the subjects having different electrophoretic variants and TfC subtypes of transferrin were not significantly different from each other. There was no significant difference of TIBC in relation to different electrophoretic variants of Tf. However, the TIBC of the subjects of the 1-1 subtype of TfC (70.4 +/- 13.6 mumol/l) was significantly higher than that of the 2-1 subtype (65.0 +/- 12.8 mumol/l; p less than 0.05) as well as that of the 2-2 subtype (60.4 +/- 11.4 mumol/l; p less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3096053     DOI: 10.1159/000206128

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  8 in total

1.  HFE mutations and transferrin C1/C2 polymorphism among Croatian patients with schizophrenia and schizoaffective disorder.

Authors:  Alena Buretić-Tomljanović; Jadranka Vraneković; Gordana Rubeša; Suzana Jonovska; Draško Tomljanović; Vesna Sendula-Jengić; Miljenko Kapović; Smiljana Ristić
Journal:  Mol Biol Rep       Date:  2011-06-04       Impact factor: 2.316

2.  Effect modification by transferrin C2 polymorphism on lead exposure, hemoglobin levels, and IQ.

Authors:  Ananya Roy; Adrienne S Ettinger; Howard Hu; David Bellinger; Joel Schwartz; Rama Modali; Robert O Wright; Kavitha Palaniappan; Kalpana Balakrishnan
Journal:  Neurotoxicology       Date:  2013-05-31       Impact factor: 4.294

3.  Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease.

Authors:  K J H Robson; D J Lehmann; V L C Wimhurst; K J Livesey; M Combrinck; A T Merryweather-Clarke; D R Warden; A D Smith
Journal:  J Med Genet       Date:  2004-04       Impact factor: 6.318

4.  5- and 6-glycosylation of transferrin in patients with Alzheimer's disease.

Authors:  Susan J van Rensburg; Peter Berman; Felix Potocnik; Pam MacGregor; Dinie Hon; Nico de Villiers
Journal:  Metab Brain Dis       Date:  2004-06       Impact factor: 3.584

5.  Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases.

Authors:  Veronica Tisato; Giovanni Zuliani; Marco Vigliano; Giovanna Longo; Eugenia Franchini; Paola Secchiero; Giorgio Zauli; Elvezia Maria Paraboschi; Ajay Vikram Singh; Maria Luisa Serino; Beatrice Ortolani; Amedeo Zurlo; Cristina Bosi; Antonio Greco; Davide Seripa; Rosanna Asselta; Donato Gemmati
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

6.  Polymorphisms in the genes coding for iron binding and transporting proteins are associated with disability, severity, and early progression in multiple sclerosis.

Authors:  Donato Gemmati; Giulia Zeri; Elisa Orioli; Francesca E De Gaetano; Fabrizio Salvi; Ilaria Bartolomei; Sandra D'Alfonso; Claudia Dall'osso; Maurizio A Leone; Ajay V Singh; Rosanna Asselta; Paolo Zamboni
Journal:  BMC Med Genet       Date:  2012-08-10       Impact factor: 2.103

7.  Genetic variants of transferrin in cystic fibrosis.

Authors:  E Marklová; Z Albahri; H Vanícek; P Dedek; M Valis; M Kopácová; V Vávrová
Journal:  J Inherit Metab Dis       Date:  2008-02-22       Impact factor: 4.750

8.  Iron metabolism genes, low-level lead exposure, and QT interval.

Authors:  Sung Kyun Park; Howard Hu; Robert O Wright; Joel Schwartz; Yawen Cheng; David Sparrow; Pantel S Vokonas; Marc G Weisskopf
Journal:  Environ Health Perspect       Date:  2008-08-22       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.